Dopaminergic genotype of schizophrenic patients and the benefit of adjunctive aripiprazole to risperidone treatment. The effect on hormonal and metabolic measures

• Conditions: schizophrenia; MedDRA version: 16.0Level: PTClassification code 10039626Term: SchizophreniaSystem Organ Class: 10037175 - Psychiatric disorders; Therapeutic area: Psychiatry and Psychology [F] - Psychological processes [F02]

• Registration Number: EUCTR2013-001315-71-ES
• Lead Sponsor: Mercedes Zumarraga Ortiz

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2013-06-26
• Last Update Posted: 26 November 2013

Recruitment & Eligibility

• Status: Authorised-recruitment may be ongoing or finished
• Sex: All
• Target Recruitment: 110

Inclusion Criteria

..
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 110
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

..

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Main Objective: ..;Secondary Objective: not applicable;Primary end point(s): ..;Timepoint(s) of evaluation of this end point: ..

Secondary Outcome Measures

Name	Time	Method
Secondary end point(s): ..;Timepoint(s) of evaluation of this end point: ..